Review of the top 5 cardiology studies of 2015-16

Abstract

Get full access to this article

View all access options for this article.

References

Barry

Boswell

Law

et al . Review of the top 5 cardiology studies of 2011-12. Can Pharm J (Ott) 2013;146:213-7.

Barry

Basaraba

Bong

et al . Review of the top 5 cardiology studies of 2013-14. Can Pharm J (Ott) 2015;148:349-54.

The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103-16.

Green

Bethel

Armstrong

et al . Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42.

Pfeffer

Claggett

Diaz

et al . Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57.

Marso

Bain

Consoli

et al . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44.

Zinman

Wanner

Lachin

et al . Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.

Marso

Daniels

Brown-Frandsen

et al . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-22.

Cannon

Blazing

Giugliano

et al . Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015:372:2387-97.

10.

Nissen

Yeomans

Soloman

et al . Cardiovascular safety of celecoxib, naproxen or ibuprofen for arthritis. N Engl J Med 2016;375:2519-29.

11.

Tsuyuki

Al Hamarneh

Jones

Hemmelgarn

BR.

The effectiveness of pharmacist interventions on cardiovascular risk: the multicenter randomized controlled RxEACH trial. J Am Coll Cardiol 2016;67:2846-54.

12.

Douketis

Spyropolous

Kaatz

et al . Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-33.

13.

Yusuf

Bosch

Dagenais

et al . Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 2016;374:2021-31.

14.

Fiedler

Maeng

Mahilli

et al . Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol 2015;65:1619-29.

15.

Pollack

Reilly

Eikleboom

et al . Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:511-20.

16.

Bonaca

Bhatt

Cohen

et al . Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800.

17.

Gillinov

Bagiella

Moskowitz

et al . Rate versus rhythm control for atrial fibrillation after cardiac surgery. N Engl J Med 2016;374:1911-21.

18.

Gibson

Mehran

Bode

et al . Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-34.

19.

Eisenburg

Windle

Roy

et al . Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation 2016;133:21-30.

20.

Robinson

Farnier

Krempf

et al . Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99.

21.

Connolly

Milling

Eikelboom

et al . Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016;375:1131-41.

22.

Leung

Daskalopoulou

Dasgupta

et al . Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol 2017;33:557-76.

23.

US Food and Drug Administration. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available: https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf (accessed March 12, 2017).

24.

Nissen

Wolski

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.

25.

Lipscombe

Butalia

Dasgupta

et al . Pharmacologic management of type 2 diabetes: 2016 interim update. Can J Diabetes 2016;40:484-6.

26.

Anderson

Grégoire

Pearson

et al . 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016;32:1263-82.

27.

US Food and Drug Administration. Public Health Advisory—FDA announces important changes and additional warnings for COX-2 selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). Available: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm150314.htm (accessed March 10, 2017).

28.

FitzGerald

GA.

Imprecision: limitations to interpretation of a large randomized clinical trial. Circulation 2017;135:113-5.

29.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013;382:769-79.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB